BiO2 Medical, developer of the Angel Catheter prophylactic pulmonary embolism protection device, said it raised $4 million, according to a regulatory filing.
The Angel catheter is designed to provide access to the central venous system and to trap blood clots before they can reach the lungs, according to the San Antonio, Texas-based company.
BiO2 Medical received $4 million of a hoped-for $10 million from 1 unnamed investor, according to an SEC filing.
In January, BiO2 won a nod from the FDA for a 182-patient pivotal trial of the device in patients at high risk for developing pulmonary embolism who can’t take standard drug therapies.
In May, BiO2 said it enrolled 40 patients within the first 3 months of the trial starting, with 13 sites actively enrolling subjects for the single-arm investigation.
BiO2, which reported raising $12 million in 2012, won CE Mark approval in the European Union for the Angel catheter in May of that year.
